Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > AGN.c +40% this week

<< Previous

Bullboard Posts

Next >>

Post by stockpatrolon Aug 26, 2022 6:46pm

165 Views

Post# 34923858

AGN.c +40% this week

https://twitter.com/Psych_Fin/status/1563268411303788545

AGN.c quickly rising in popularity recently becoming NIA’s top biotech stock. As well as their largest share holder AlphaNorth Assets increasing their equity interest in AGN.c by over 13%. Phase 2 study results of fenprodil for Idiopathic Pulmonary Fibrosis & Chronic Cough should be released sometime soon. Phase 1 of DMT trials set to begin next month.

<< Previous

Bullboard Posts

Next >>

HPQ Silicon updates shareholders on Fumed Silica Reactor developments